Pharma Strategy Blog

Commentary on Pharma & Biotech Oncology / Hematology New Product Development

Posts tagged ‘Seattle Genetics’

Seattle Genetics announce fast track approval of Adcetris

By on August 22, 2011

This morning, Seattle Genetics announced that the expected fast track approval from the FDA has been forthcoming for brentuximab vedotin (Adcetris) following the recent unanimous ODAC voting in both refractory Hodgkin Lymphoma (HL) and Anaplastic Large Cell Lymphoma (ALCL).  Clearly, the company and the agency have come to agreement on the confirmatory trials as part of the condition of accelerated review.  The final prescribing information (PI) can be found on the Adcetris website.

For those of you looking for more information on Adcetris, please check out the related posts section below for previous reports on this novel ADC therapy.

This is a preview of Seattle Genetics announce fast track approval of Adcetris. Read the full post

2 Comments

Antibody Drug Conjugates (ADCs) in cancer research: what are they?

By on May 25, 2011

Quite a few questions have hit my inbox recently from people wanting to know more about Antibody Drug Conjugates (ADCs) and how they work.

They basically consist of three things:

  1. Monoclonal antibody
  2. Linker
  3. Cytotoxic agent

Antibody Drug Conjugate (ADC)

Source: Roche

The goal is to create a new molecule that essentially is greater than the sum of its parts by making it more targeted, like a guided missile against the cancer cells.

This is a preview of Antibody Drug Conjugates (ADCs) in cancer research: what are they?. Read the full post

14 Comments

Seattle Genetics brentuximab vedotin accepted for FDA Priority review

By on May 2, 2011

I was delighted to see, amongst all the big news this morning on President Obama and Osama Bin Laden, that there was a little gem for Biotech – Seattle Genetics announced that the FDA have accepted their BLA filings for antibody drug conjugate (ADC), brentuximab vedotin, and awarded Priority status.  The company stated that the Prescription Drug User Fee Act (PDUFA) date is now set for August 30th, based on the Feb 28th filing date.

Two BLA filings were submitted, one for relapsed Hodgkin Lymphoma (HL) and another for relapsed or refractory systemic anaplastic large cell lymphoma (ALCL).  These two hematologic cancers share a commonality, ie CD30, which is the defining marker of the disease and the target for the ADC therapy.

This is a preview of Seattle Genetics brentuximab vedotin accepted for FDA Priority review. Read the full post

Interesting new data at ASH for cancer biotech Seattle Genetics

By on December 10, 2008

There have been a number of interesting early phase compounds with new data being reported at American Society of Hematology (ASH) meeting this weekend, some of these will be described over the next few days.Seattle Genetics has a number of monoclonal antibodies in development for the treatment of hematologic malignancies.  One of them, SGN-35, is an antibody conjugate that targets CD-30 cells and hence is being evaluated in CD-30 positive malignancies such as Hodgkins Lymphoma.  There was an interesting poster published here (PDF) at the ASH meeting.

This is a preview of Interesting new data at ASH for cancer biotech Seattle Genetics. Read the full post

2 Comments
error:
error: Content is protected !!